Pfizer and Valneva announced that their Lyme disease vaccine candidate, PF-07307405, has shown over 70% efficacy in clinical trials, paving the way for marketing authorization. The vaccine is well tolerated and has completed two Phase 3 trials, demonstrating a significant reduction in Lyme disease cases. Currently, there are no approved vaccines for Lyme disease, making this development crucial. Teljes cikk (Euronews.com)